ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailPositive ArrowIcon Print
Pharmaceuticals

Eisai-Biogen Alzheimer's drug draws doubt from European regulators

Vote by European Medicines Agency panel deals setback to controversial $56,000-a-year treatment

Aduhelm, the drug U.S.-based Biogen has developed with Japan's Eisai, received a "negative trend vote" from the Committee for Medicinal Products for Human Use panel.

LONDON/NEW YORK (Financial Times) -- A key European Medicines Agency panel has signaled it is unlikely to grant approval to Biogen's drug for Alzheimer's disease, adding to the debate surrounding a controversial treatment that retails at $56,000 a year.

On Wednesday, Biogen said Aduhelm, the drug it has developed with Japan's Eisai, received a "negative trend vote" from the Committee for Medicinal Products for Human Use panel on its application for marketing authorization in the bloc. The panel is expected to give its formal decision next month, Biogen said.

Sponsored Content

About Sponsored Content This content was commissioned by Nikkei's Global Business Bureau.

Discover the all new Nikkei Asia app

  • Take your reading anywhere with offline reading functions
  • Never miss a story with breaking news alerts
  • Customize your reading experience

Nikkei Asian Review, now known as Nikkei Asia, will be the voice of the Asian Century.

Celebrate our next chapter
Free access for everyone - Sep. 30

Find out more